{"schema_version":"secwatch.filing_event.v1","accession":"0001127537-23-000005","form_type":"8-K","ticker":"LUNG","cik":"0001127537","company_name":"Pulmonx Corp","filed_at":"2023-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.935164+00:00","generated_at":"2026-06-19T04:12:00.651103+00:00","sec_items":["2.02","2.03","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pulmonx Q4 revenue $15.4M (+13% YoY); draws $20M debt; FY23 guidance $63-65M","bullets":["Q4 2022 revenue $15.4M, up 13% YoY; U.S. revenue $9.5M (+30% YoY).","Full year 2022 revenue $53.7M, up 11% YoY; net loss $58.9M ($1.59/share).","FY2023 revenue guidance $63-65M; gross margin 73-74%; operating expenses $112-114M.","Drew $20M from CIBC loan on Feb 21, 2023; floating rate at Prime +1%.","Added 17 new U.S. treatment centers in Q4, total 278; preparing for Japan launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001127537-23-000005","json":"https://secwatch.observer/filing/0001127537-23-000005.json","markdown":"https://secwatch.observer/filing/0001127537-23-000005.md","text":"https://secwatch.observer/filing/0001127537-23-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1127537/000112753723000005/0001127537-23-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1127537/000112753723000005/lung-20230222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T04:12:00.651103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0515169ece3c38b65352fc7324dd1fbd4eabf2e6","claim":"Pulmonx Corp incurred credit facility of $20.0 million with Canadian Imperial Bank of Commerce at 1.0% above the Wall Street Journal Prime Rate.","evidence_excerpt":"On February 21, 2023, the Company exercised its option to draw $20.0 million available under a Loan and Security Agreement with Canadian Imperial Bank of Commerce (“CIBC”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1127537/000112753723000005/0001127537-23-000005-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"$20.0 million"},{"label":"Counterparty","value":"Canadian Imperial Bank of Commerce"},{"label":"Rate","value":"1.0% above the Wall Street Journal Prime Rate"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"3634938fff3e855905287de0ad52a0a9c281d9ca","claim":"Pulmonx Corp reported the full year of 2022 results: revenue $53.7 million, net income $58.9 million, EPS $1.59 per share.","evidence_excerpt":"invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2022 ended December 31, 2022. Recent Highlights • Delivered $53.7 million in worldwide revenue for the full year of 2022 • Achieved record worldwide revenue of $15.4 million for the fourth quarter of 2022, a 13% increase over the same period last year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1127537/000112753723000005/0001127537-23-000005-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year of 2022"},{"label":"Revenue","value":"$53.7 million"},{"label":"Net income","value":"$58.9 million"},{"label":"EPS","value":"$1.59 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"8ae93247ecdd7cfd4d17fab1206b3a26c7a32e34","claim":"Pulmonx Corp reported the full year 2023 results: revenue $63 million to $65 million. Guidance initiated.","evidence_excerpt":"Pulmonx expects revenue for the full year 2023 to be in the range of $63 million to $65 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1127537/000112753723000005/0001127537-23-000005-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year 2023"},{"label":"Revenue","value":"$63 million to $65 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"e60f2918e69c348e247a37d2fb7f70e785851020","claim":"Pulmonx Corp reported the fourth quarter of 2022 results: revenue $15.4 million, net income $14.3 million, EPS $0.38 per share.","evidence_excerpt":"and full year of 2022 ended December 31, 2022. Recent Highlights • Delivered $53.7 million in worldwide revenue for the full year of 2022 • Achieved record worldwide revenue of $15.4 million for the fourth quarter of 2022, a 13% increase over the same period last year and an increase of 18% in constant currency • Set a new record of $32.5 million and $9.5 million in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1127537/000112753723000005/0001127537-23-000005-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2022"},{"label":"Revenue","value":"$15.4 million"},{"label":"Net income","value":"$14.3 million"},{"label":"EPS","value":"$0.38 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}